Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia

Journal of Paediatrics and Child Health

Volumn 48, Issue 8, 2012, Pages 634-640

  Bhadri, Vivek A ^a,b   Trahair, Toby N ^a,b   Lock, Richard B ^b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

glucocorticoid; haematology; leukaemia; oncology

Indexed keywords

ARSENIC TRIOXIDE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MESSENGER RNA; METHOTREXATE; MIXED LINEAGE LEUKEMIA PROTEIN; PREDNISOLONE; PROTEIN BCL 2; SHORT HAIRPIN RNA; TRIAMCINOLONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LYMPHOMA; CELL DEATH; CELL VIABILITY; DOSE RESPONSE; DRUG EXPOSURE; HUMAN; LYMPHOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

CHILD; DRUG RESISTANCE, NEOPLASM; GLUCOCORTICOIDS; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84864688676     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2011.02212.x     Document Type: Review

References (55)

1. Australian Institute of Health and Welfare (AIHW), McDermid I,. Cancer Incidence Projections Australia 2002 to 2011. AIHW, 2005.
2. Pui CH, Evans WE,. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 2006; 354: 166-78. (Pubitemid 43076714)
3. Reiter A, Schrappe M, Ludwig WD, et al,. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-33. (Pubitemid 24328106)
4. Roy A, Cargill A, Love S, et al,. Outcome after first relapse in childhood acute lymphoblastic leukaemia-lessons from the United Kingdom R2 trial. Br. J. Haematol. 2005; 130: 67-75. (Pubitemid 40979134)
5. Conter V, Bartram CR, Valsecchi MG, et al,. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-14.
6. Gaynon PS, Carrel AL,. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv. Exp. Med. Biol. 1999; 457: 593-605. (Pubitemid 129735357)
7. Hyman CB, Sturgeon P,. Prednisone therapy of acute lymphatic leukemia in children. Cancer 1956; 9: 965-70.
8. Riehm H, Reiter A, Schrappe M, et al,. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin. Padiatr. 1987; 199: 151-60. (Pubitemid 17079852)
9. Dordelmann M, Reiter A, Borkhardt A, et al,. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-17. (Pubitemid 29380401)
10. Schrappe M, Reiter A, Zimmermann M, et al,. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000; 14: 2205-22. (Pubitemid 32042262)
11. Moricke A, Reiter A, Zimmermann M, et al,. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-89.
12. Klumper E, Pieters R, Veerman AJ, et al,. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995; 86: 3861-8.
13. Baxter JD, Harris AW, Tomkins GM, Cohn M,. Glucocorticoid receptors in lymphoma cells in culture: relationship to glucocorticoid killing activity. Science 1971; 171: 189-91.
14. Yamamoto KR, Alberts BM,. Steroid receptors: elements for modulation of eukaryotic transcription. Annu. Rev. Biochem. 1976; 45: 721-46.
15. Drouin J, Charron J, Gagner JP, et al,. Pro-opiomelanocortin gene: a model for negative regulation of transcription by glucocorticoids. J. Cell. Biochem. 1987; 35: 293-304. (Pubitemid 18019040)
16. Drexler HG, Fombonne S, Matsuo Y, Hu ZB, Hamaguchi H, Uphoff CC,. p53 alterations in human leukemia-lymphoma cell lines: in vitro artifact or prerequisite for cell immortalization? Leukemia 2000; 14: 198-206. (Pubitemid 30068392)
17. Gruber G, Carlet M, Turtscher E, et al,. Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosis. Leukemia 2009; 23: 820-3.
18. Schmidt S, Irving JA, Minto L, et al,. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor. Faseb J. 2006; 20: 2600-2.
19. Geley S, Hartmann BL, Hala M, Strasser-Wozak EM, Kapelari K, Kofler R,. Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression. Cancer Res. 1996; 56: 5033-8. (Pubitemid 26374445)
20. Tissing WJ, Meijerink JP, Brinkhof B, et al,. Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL. Blood 2006; 108: 1045-9. (Pubitemid 44154643)
21. Lauten M, Cario G, Asgedom G, Welte K, Schrappe M,. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia. Haematologica 2003; 88: 1253-8. (Pubitemid 37456380)
22. Koga Y, Matsuzaki A, Suminoe A, Hattori H, Kanemitsu S, Hara T,. Differential mRNA expression of glucocorticoid receptor alpha and beta is associated with glucocorticoid sensitivity of acute lymphoblastic leukemia in children. Pediatr. Blood Cancer 2005; 45: 121-7. (Pubitemid 40993576)
23. Haarman EG, Kaspers GJ, Pieters R, Rottier MM, Veerman AJ,. Glucocorticoid receptor alpha, beta and gamma expression vs. in vitro glucocorticod resistance in childhood leukemia. Leukemia 2004; 18: 530-7. (Pubitemid 38425868)
24. Beesley AH, Weller RE, Senanayake S, Welch M, Kees UR,. Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines. Leuk. Res. 2009; 33: 321-5.
25. Bachmann PS, Gorman R, Mackenzie KL, Lutze-Mann L, Lock RB,. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood 2005; 105: 2519-26. (Pubitemid 40387054)
26. Kojika S, Sugita K, Inukai T, et al,. Mechanisms of glucocorticoid resistance in human leukemic cells: implication of abnormal 90 and 70 kDa heat shock proteins. Leukemia 1996; 10: 994-9. (Pubitemid 26235933)
27. Lauten M, Beger C, Gerdes K, et al,. Expression of heat-shock protein 90 in glucocorticoid-sensitive and -resistant childhood acute lymphoblastic leukaemia. Leukemia 2003; 17: 1551-6. (Pubitemid 36986957)
28. Tissing WJ, Meijerink JP, den Boer ML, Brinkhof B, Pieters R,. mRNA expression levels of (co)chaperone molecules of the glucocorticoid receptor are not involved in glucocorticoid resistance in pediatric ALL. Leukemia 2005; 19: 727-33. (Pubitemid 40663091)
29. Strasser A,. The role of BH3-only proteins in the immune system. Nat. Rev. Immunol. 2005; 5: 189-200. (Pubitemid 40364821)
30. Huang DC, Strasser A,. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000; 103: 839-42.
31. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB,. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev. 2001; 15: 1481-6. (Pubitemid 32552527)
32. Wang Z, Malone MH, He H, McColl KS, Distelhorst CW,. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J. Biol. Chem. 2003; 278: 23861-7. (Pubitemid 36830212)
33. Schmidt S, Rainer J, Riml S, et al,. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood 2006; 107: 2061-9. (Pubitemid 43292367)
34. Medh RD, Webb MS, Miller AL, et al,. Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics 2003; 81: 543-55. (Pubitemid 36627498)
35. Planey SL, Abrams MT, Robertson NM, Litwack G,. Role of apical caspases and glucocorticoid-regulated genes in glucocorticoid-induced apoptosis of pre-B leukemic cells. Cancer Res. 2003; 63: 172-8. (Pubitemid 36070437)
36. Bachmann PS, Gorman R, Papa RA, et al,. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res. 2007; 67: 4482-90. (Pubitemid 46815099)
37. Abrams MT, Robertson NM, Yoon K, Wickstrom E,. Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J. Biol. Chem. 2004; 279: 55809-17. (Pubitemid 40066588)
38. Lu J, Quearry B, Harada H,. p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells. FEBS Lett. 2006; 580: 3539-44. (Pubitemid 44208999)
39. Ploner C, Rainer J, Niederegger H, et al,. The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia. Leukemia 2008; 22: 370-7. (Pubitemid 351250542)
40. Stam RW, Den Boer ML, Schneider P, et al,. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2009; 115: 1018-25.
41. Jaattela M,. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004; 23: 2746-56. (Pubitemid 38638838)
42. Gozuacik D, Kimchi A,. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004; 23: 2891-906. (Pubitemid 38638851)
43. Laane E, Tamm KP, Buentke E, et al,. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ. 2009; 16: 1018-29.
44. Bonapace L, Bornhauser BC, Schmitz M, et al,. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J. Clin. Invest. 2010; 120: 1310-23.
45. Soignet SL, Maslak P, Wang ZG, et al,. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 1998; 339: 1341-8. (Pubitemid 28509343)
46. Tabellini G, Tazzari PL, Bortul R, et al,. Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. Br. J. Haematol. 2005; 130: 716-25.
47. Bornhauser BC, Bonapace L, Lindholm D, et al,. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood 2007; 110: 2084-91. (Pubitemid 47443926)
48. Wei G, Twomey D, Lamb J, et al,. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 331-42. (Pubitemid 44512194)
49. Holleman A, Cheok MH, Den Boer ML, et al,. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 2004; 351: 533-42.
50. Hulleman E, Kazemier KM, Holleman A, et al,. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2009; 113: 2014-21.
51. Eberhart K, Renner K, Ritter I, et al,. Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis. Leukemia 2009; 23: 2167-70.
52. Weng AP, Ferrando AA, Lee W, et al,. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-71. (Pubitemid 39336870)
53. De Keersmaecker K, Lahortiga I, Mentens N, et al,. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 2008; 93: 533-42. (Pubitemid 351536381)
54. Searfoss GH, Jordan WH, Calligaro DO, et al,. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J. Biol. Chem. 2003; 278: 46107-16. (Pubitemid 37432761)
55. Real PJ, Tosello V, Palomero T, et al,. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat. Med. 2009; 15: 50-8.